Hims & Hers weight loss adds compounded GLP-1 injections

Hims & Hers weight loss adds compounded GLP-1 injections

Products of Hims & Hers displayed. Hims & Hers Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday. The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 … Read more

Roche weight loss drug shows promising results in early trial

Roche weight loss drug shows promising results in early trial

A logo at the Roche Holding AG headquarters in Basel, Switzerland, on Thursday, Feb. 1, 2024. Bloomberg | Getty Images Roche on Thursday said its experimental weight loss drug showed promising results in an early-stage trial, boosting the company’s bid to compete in the booming market for those treatments. The Swiss company joined a slate of … Read more

1 in 8 adults have taken GLP-1s like Ozempic: survey

1 in 8 adults have taken GLP-1s like Ozempic: survey

Rebekah Carl poses with her prescription of Wegovy in New Columbia, Pennsylvania, U.S., November 13, 2023.  Hannah Beier | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The use of a buzzy class of weight loss and diabetes medications is more common … Read more

Wegovy patients maintain weight loss for 4 years: Novo Nordisk study

Wegovy patients maintain weight loss for 4 years: Novo Nordisk study

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.  Hollie Adams | Reuters Patients taking Novo Nordisk‘s obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis published Tuesday from the longest clinical trial to date … Read more

Eli Lilly, Novo Nordisk boost weight loss drug supply

Eli Lilly, Novo Nordisk boost weight loss drug supply

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! A highly popular group of weight loss and diabetes drugs is still hard … Read more

Amgen could threaten Novo Nordisk, Eli Lilly weight loss drug dominance

Amgen could threaten Novo Nordisk, Eli Lilly weight loss drug dominance

The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat from a new rival.  Amgen … Read more

Amgen soars on weight loss drug progress, Novo Nordisk, Eli Lilly slide

Amgen soars on weight loss drug progress, Novo Nordisk, Eli Lilly slide

Pavlo Gonchar | Lightrocket | Getty Images Amgen‘s stock rose more than 12% on Friday after the drugmaker teased positive initial data on its experimental weight loss injection.  That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly, … Read more

Amgen scraps experimental weight loss pill, moves forward with injection

Amgen scraps experimental weight loss pill, moves forward with injection

The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. Amgen is among several drugmakers racing … Read more

Novo Nordisk earnings Q1 2024, Wegovy sales double

Novo Nordisk earnings Q1 2024, Wegovy sales double

The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk, which became the most valuable company in Europe last year due to the blockbuster success of its weight loss drugs, on Thursday beat first-quarter profit expectations as demand for … Read more

Eli Lilly (LLY) says it can overcome high-quality problem of too much demand

Eli Lilly (LLY) says it can overcome high-quality problem of too much demand

Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in the three months ended March … Read more